ATG brings leading-edge antimicrobial technologies to Berlin Life Sciences Conference
Press Release | ATG:biosynthetics GmbH
FEBRUARY 14, 2017
Merzhausen, Germany: – German-based contract research organization ATG:biosynthetics (ATG) will be an important presence at the 2017 Berlin Conference on Life Sciences as it focuses on novel antimicrobial technologies.
ATG is a leader in this field with its expertise in bioinformatics, synthetic biology, gene and pathway design, library and expression vector design/synthesis and its novel Epitope mapping service that combines computational analysis of a pathogen genome with PepID biopeptides expression technology.
ATG’s strong PepID’s computational algorithms allow it to generate deterministic DNA-encoded peptide libraries that can then be expressed on antibody recognition, either by colony immunoblotting or using cell surface display. The new methodology aims to maximize the efficacy of multi-epitope vaccines.
Antimicrobial drug design
The conference, now in its tenth year, is being held at the British Embassy in Berlin, where ATG will be represented by its CEO, Dr. Hubert S. Bernauer.
“The Berlin Life Sciences Conference is a highly esteemed event that gives us a great opportunity to meet other eminent colleagues in the field and establish contact with other SMEs,” said Dr. Bernauer.
“It is a also a rich source of industry-leading thought and perspectives, where we can gather new inspiration for our future avenues of research and business development in antimicrobial drug design,” Dr. Bernauer added.
About ATG: biosynthetics
Advanced Technical Genetomics (ATG) is a German-based company that specializes in synthetic biology, combinatorial gene design and multi-gene expression. Located in Merzhausen near Freiburg, ATG offers a complete range of multi-gene and multi-peptide expression products and services for synthetic and molecular biology as well as allied research and development areas.
ATG: biosynthetics possesses particular strengths in designing tailor-made solutions (e.g., gene cluster and complete pathway designs) that harness its technologies and services in related product areas that include gene synthesis, bioinformatics, molecular in silico biodesign, epitope mapping and pathway engineering. These provide clients with individual products and services or integrated solutions that offer a complete product & service package for peptide/gene expression and synthetic biology applications.
ATG seeks partnerships and outsourcing projects that aim at developing and marketing high-potential applications, e.g. creating high efficiency DNA- and protein-based vaccines.
About Berlin Conference on Life Sciences
Over its ten-year history, the Berlin Conference on Life Sciences has become a highly respected annual event for Life Science decision makers, business developers, investors and legal experts.
The 10th Berlin Conference on Life Sciences is a one-day event on February 24, 2017, held at the British Embassy on Berlin’s historic Wlhelmstrasse.
The upcoming conference will focus on the exciting market and challenging conditions for the development of Novel Antimicrobials. Conference sessions include an industry overview, R&D trends and a technology perspective on new approaches to efficiently combating antimicrobial resistance, discussion of the legal and regulatory environment and a Start-up Pitch that allows Investors to hear direct from innovators in the sector.
Speakers will cover the entire value chain from research & development to the market.
The event is organized by Biocom AG, with more information at: http://berlin-conferences.com/home/
Dr. Hubert S. Bernauer, CEO, ATG:biosynthetics GmbH
Tel: +49 (0)761 888 9424
Click on ATG brings leading-edge antimicrobial technologies to Berlin Life Sciences Conference for more information.
Click on ATG to contact the company directly.